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Osteoarthritis (OA) is a heterogeneous disorder. The goals of this review are (1) To stimulate use of
standardized nomenclature for OA that could serve as building blocks for describing OA and deﬁning OA
phenotypes, in short to provide unifying disease concepts for a heterogeneous disorder; and (2) To
stimulate establishment of ROAD (Risk of OA Development) and ROAP (Risk of OA Progression) tools
analogous to the FRAX™ instrument for predicting risk of fracture in osteoporosis; and (3) To stimulate
formulation of tools for identifying disease in its early preradiographic and/or molecular stages e REDI
(Reliable Early Disease Identiﬁcation). Consensus around more sensitive and speciﬁc diagnostic criteria
for OA could spur development of disease modifying therapies for this entity that has proved so recal-
citrant to date. We fully acknowledge that as we move forward, we expect to develop more sophisticated
deﬁnitions, terminology and tools.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Purpose
New speciﬁc and sensitive disease endpoints are critically
needed to alleviate roadblocks to development of disease modi-
fying therapeutics and strategies for secondary prevention of
osteoarthritis (OA). A key step in this process is the development of
standardized deﬁnitions of OA. Standardization of OA deﬁnitions
would aid communication across the ﬁeld and help advance drug
development for OA and research by achieving consensus on
globally recognized deﬁnitions of disease and globally recognized
standards for classifying the disease. We anticipate that these
deﬁnitions could facilitate communication about the disease
among industry and non-industry researchers, regulatory agencies,
funding agencies, third party payers, and patients. We further: V.B. Kraus, Duke Molecular
Duke University School of
ternational. Published by Elsevier Lanticipate that these deﬁnitions would be maintained by the OA
Research Society International (OARSI) and subjected to regular
reﬁnement as new scientiﬁc advances demand. Deﬁnitions pro-
posed are not intended to distinguish an OA patient uniquely from
patients with other forms of arthritis; rather, the draft deﬁnitions
can be viewed as the building blocks for deﬁning OA phenotypes.
We fully acknowledge that these building blocks are likely most
applicable to knee and hip OA, possibly helpful for hand OA, but will
require modiﬁcation for spine OA. In this review we therefore
propose broad OA deﬁnitions with the intent to reﬁne them
through “crowd-sourcing” from the OARSI membership via a WIKI
on the OARSI website.
Outdated disease classiﬁcation system
According to the United States (US) Food and Drug Adminis-
tration (FDA)1, “Currently used disease classiﬁcation systems deﬁne
diseases primarily on the basis of their signs and symptoms. These
systems do not easily accommodate emerging information about
diseasemechanisms, particularly when it is at odds with traditionaltd. All rights reserved.
Fig. 1. Relationships of disease and illness components. We posit that the disease may
be manifest by a prolonged period of isolated musculoskeletal tissue abnormalities at a
molecular and clinically silent level (molecular). Further, the molecular abnormalities
could precede the anatomic and physiologic level organ system disease and illness
manifestations by years or even decades. In addition, abnormalities of two domains or
all in combination could be imagined (depicted by arrows and the ring connecting the
components).
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distinct molecular causes are still classiﬁed as one disease, while
multiple, different diseases that share a common molecular cause
are not properly linked. The failure of our outdated disease classi-
ﬁcation systems to incorporate optimally new biological insights
serves as a fundamental barrier to progress in personalized medi-
cine. The US National Academy of Sciences has called for the cre-
ation of a 'New Taxonomy' of disease that is designed to advance
our understanding of disease pathogenesis and improve health and
that deﬁnes and describes diseases on the basis of their intrinsic
biology in addition to traditional signs and symptoms2.”
Several different strategies have been proposed for describing
OA phenotypes, including phenotyping based on modern imaging3
or pathophysiological mechanisms4. Based on phenotypes, OA is
considered highly heterogeneous. Nevertheless, it is often consid-
ered a common pathological process triggered by a variety of
inciting events and agents. These entities that share a common
molecular cause would beneﬁt from a ‘new taxonomy’ that would
enable us to communicate about the disease on the basis of
intrinsic characteristics. The purpose here is to begin to develop
and reach consensus on a shared nomenclature. This would be
designed to facilitate our understanding of the pathogenesis of OA
and would be updated and reﬁned as new disease insights are
gained. The US National Research Council Committee suggested a
framework for creating an information system called a Knowledge
Network of disease that integrates the rapidly expanding range of
information on the causes of disease and allows researchers,
health-care providers, and the public to share and update this in-
formation2. Such a long-term goal is indeed tantalizing for OA, and
could be envisioned as an ongoing project by the OARSI
membership.
Disease vs illness
“Disease” refers to abnormalities of the structure and function of
body organs and systems that can be speciﬁcally identiﬁed and
described by reference to certain biological, chemical or other ev-
idence5. A disease has speciﬁc properties and a recurring identity in
whichever setting it appears. Because a particular disease is
assumed to be universal in its form, progress and content5, we seek
here to deﬁne OA as disease, not by patient phenotype but rather by
its universal form.
An “illness” refers to the human response to disease5. Cassell in
1978 described illness to mean “what the patient feels when he
goes to the doctor”, and disease to mean “what he has on the way
home from the doctor's ofﬁce”; in short, disease is something an
organ has and illness is something a person has (summarized by
Helman5). The speciﬁc manifestations of illness are likely to differ
according to OA phenotype. Although they may coexist, and often
do, it is possible for disease to occur in the absence of illness. Like
osteoporosis, OA may be manifest by a prolonged period of
musculoskeletal tissue abnormalities at a molecular but clinically
silent level that can precede the anatomic organ system disease and
illness manifestations by years or even decades (Fig. 1). Thus, very
early OAwould be characterized by an asymptomatic disease state.
It is common in OA that disease does not coincide with illness;
deﬁnite radiographic features of OA are often found in joints of
persons without symptoms. In this sense, the disease and its
radiographic features could be considered risk factors for the
illness. A precedent exists in spondyloarthropathies for which
preradiographic diagnostic disease criteria were developed6 that
subsequently stimulated treatment trials7. By analogy, we hope that
a greater understanding and consensus regarding the disease vs
illness aspects of OA would similarly stimulate treatment trials for
early OA.There is much we do not know about the chronology of the OA
trajectory frommolecular disease to anatomic disease to illness. As
noted in Fig. 1, we posit that molecular abnormalities may coexist
with anatomic abnormalities in the absence of illness; we observe
this as radiographic or magnetic resonance imaging (MRI) abnor-
malities in the absence of symptoms. We also posit that molecular
abnormalities may coexist with illness in the absence of measur-
able anatomic abnormalities; this may be due, for instance, to
cartilage degradation products activating innate immunity, sub-
clinical synovitis and pain in the absence of discernible anatomic
derangements by the current imaging tools. Illness might also
occur in the absence of discernible disease; if truly OA related, then
this could be due to a lack of sensitive enough biochemical and
imaging biomarker tools to detect disease. In OA, it will be chal-
lenging to conﬁdently rule out disease at early stages until we have
sensitive tools for identifying the early molecular derangements of
the joint organ. Of course, any aspect of disease may coexist with
illness8.
In addition to illness and molecular and anatomic aspects of
disease, there can be physiologic aspects of disease [Fig. 2(A)]. It is
said that anatomy studies the form, while physiology looks at the
function e anatomy looks at what it is, while physiology looks at
what it does3. A holistic description of the pathology requires an
understanding and description of all these aspects. Consider the
real life illustration of these concepts for the example of heart
failure. The anatomic severity of heart failure can be quantiﬁed by
degree of left ventricular dilatation. The physiologic severity of
heart failure can be quantiﬁed by percent ejection fraction. There
are evenmolecular biomarkers, such B-type natriuretic protein and
N-terminal pro-B-type natriuretic peptide, produced by the ven-
tricles in the heart in response to excessive stretching of heart
muscle cells, that correlatewith severity of heart failure, and whose
use clinically may be superior to symptom-guided therapy9,10.
Multiple symptoms of illness can arise in heart failure, among them
most notably, shortness of breath. Now consider a possible example
for OA [Fig. 2(B)]. The anatomic severity of knee OA can be
Fig. 2. Taxonomy of OA. We propose a new ‘taxonomy of OA’ based on the standardized nomenclature of disease (made up of molecular, anatomic and physiologic components,
domains or disease elements) and illness (panel A). As illustrated here, a clinical threshold would be anticipated that would result in the transition from disease to illness. This
taxonomy anticipates the development of composite indices of OA (arrow) that by analogy to the DAS in rheumatoid arthritis, would encompass all three-disease domains
(molecular, anatomic and physiologic) and illness that could be useful for clinical evaluation and trials. Varying weights might be ascribed to the different elements in the composite
score (illustrated by the terms lower and higher within the arrow). OA speciﬁc examples for each domain are included in panel B.
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space narrowing) or osteophyte formation. The physiologic severity
can be quantiﬁed by cartilage indentation to measure cartilage
stiffness that sensitively reﬂects alterations in both the proteogly-
can concentration and superﬁcial collagen layer of articular carti-
lage11. The collagen II marker, urinary C-telopeptide of type II
collagen (uCTXII) could be considered the molecular biomarker
with the greatest amount of data supporting its association with
OA12. The hallmark of illness in OA is of course joint pain. These
examples illustrate the utility and clarity provided by attending to
all these aspects of pathology. This taxonomy can be applied to
deﬁne the stages of OA (Fig. 3). Below follows a more detailed
discussion of this taxonomy and these components of pathology.
The disease
Molecular indicators of joint health and disease
This level deﬁnition of OA is founded on the molecular abnor-
malities of the joint organ as detected by omics technologies such
as genomics, proteomics, transcriptomics, metabolomics etc. In
theory, a molecular level of interrogation is the only one able to
detect the very initial and very early phases of the disease process
before changes in structure are detected with for instance, radi-
ography, MRI, positron emission tomography (PET) or ultrasound. It
is anticipated that one or more biomarkers will in future be qual-
iﬁed for identifying molecular joint disease in its early stages. It isFig. 3. Stages of OA incorporating the new taxonomy. Three stages can be imagined e a n
clinical stage (with illness manifestations). The goal at the predisease stage is to promote he
inception of disease by modifying risk factors in a favorable direction. The goal at the subclin
symptomatic disease and thereby prevent illness and associated disability. The goal at the c
this includes maximizing the remaining capabilities and functions via pain management, s
(Levels of prevention adapted from Katz et al.79).also plausible that the molecular features that characterize the
abnormal joint will change within a given individual over the
course of their disease. Currently, there are only candidate bio-
markers for this early stage of disease that would be identiﬁed
solely by molecular abnormalities13e15.
Improved understanding of joint physiology and the molecular
pathogenesis of OA can potentially provide tools for deﬁning and
identifying molecular OA. To date, our understanding is that under
physiologic loading, chondrocytes maintain the balance between
degradation and synthesis of matrix macromolecules16. Under
injury or loading that exceeds the capacity of the tissue, degrada-
tion exceeds synthesis, causing joint tissue degeneration and
eventually OA16. Markers of in vivo tissue turnover (such as dea-
midated and racemized protein epitopes) suggest that cartilage is
capable of some spontaneous repair and that this response is
upregulated in OA cartilage of the knee but not the hip17e19. The
mechanisms underlying these different repair responses by joint
site are currently unknown, however, migration of cells with
chondrogenic capacity from synovium and bone marrow to
damaged cartilage has been suggested by several authors20,21.
Mechanosensors mediate the homeostatic joint response to
load16,22. Mechanoresponses of chondrocytes play an important
role in the development of OA and cartilage overloading elicits
metabolic stress reactions and enzymes that mediate tissue
degradation in vivo in a mechanosensitive manner16,23,24. Thus, an
abnormal physiology in the joint is driven by mechanical ‘wear’
that actively drives the enzymes that produce the ‘tear’23.o disease/no illness stage, a subclinical stage (with disease manifestations only) and a
alth through education on healthy lifestyle choices and speciﬁc prevention against the
ical stage is to be able to make a presymptomatic diagnosis to prevent its progression to
linical stage is to provide treatment in an effort to prevent its progression to disability;
ymptom control, stress relief, disease management, rehabilitation and risk reduction.
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relate to pathological mechanisms of OA (for review see Ref. 25).For
instance, the OA synovial ﬂuid proteome implicates proteins
related to formation and remodeling of the extracellular matrix26,
and the acute-phase response signaling pathway, the complement
pathway, and the coagulation pathway27. Indeed, proteomic ana-
lyses have deﬁned sets of serum proteins that distinguish patients
with radiographic knee OA from controls; proteins observed only in
patients with severe radiographic knee OA suggested that molec-
ular markers may become useful for staging disease28. Some other
molecular leads or ‘ﬁngerprints’ that could be helpful might include
molecular entities associated with cell stress, extracellular matrix
degradation, wound healing, pro-inﬂammatory pathways of innate
immunity, analytes associated with hypertrophic and senescent
chondrocytes, as well as hypocellularity and autophagy of
cartilage29e33. It will be important to investigate these pathways for
their ability to detect the molecular phase of the disease process as
determined by their ability to predict incident OA deﬁned by
established imaging criteria.
To date there is only scant evidence to support the ability of
these pathways to distinguish OA uniquely from other arthritis,
such as rheumatoid arthritis34. This important knowledge gap
needs to be a focus of future research. However, there are data to
suggest that cartilage from different joint sites differ in their
biochemical constituents35 and that therefore, it may ultimately be
possible to identify molecular OA according to speciﬁc joint sites.
We considered the term metabolic to describe the molecular
phase of the OA process. Although the term metabolic is attractive
for its ability to encompass the concept of joint tissue metabolism
or turnover, this term could create confusion with the metabolic
phenotype of OA (the association of OA with obesity, hypertension,
and diabetes mellitus, etc.). We therefore propose the term mo-
lecular OA as a better option to avoid confusion with the metabolic
phenotype of OA or metabolic syndrome often associated with OA.
Anatomic indicators of joint health and disease
Anatomy deals with the branch of science concerned with the
bodily structure of humans, animals, and other living organisms. In
contrast to molecular disease, deﬁned on the basis of omics tech-
nologies, the structural abnormalities comprising anatomic disease
are mainly revealed by imaging methodologies (radiography, MRI,
PET or ultrasound) or arthroscopy. By histology, the abnormalities
of OA include cartilage ﬁbrillation, ﬁssuring and denudation to
bone, loss of proteoglycan, chondrocyte death or proliferation and
osteophyte formation36. By radiography, the primary anatomic
abnormalities of OA are loss of articular and meniscal cartilage
(reﬂected in joint space narrowing), osteophyte formation, bone
sclerosis and bone cysts, pathological bone contour alterations and
joint malalignment. By MRI more subtle anatomic abnormalities
are discernible37e39. These structural changesmay be present in the
absence of the illness characterized by the experience of pain or
other symptoms38; therefore, an anatomic description of the dis-
ease can be independent of illness (as described below). For
example, early disease may be characterized by increased cartilage
thickness and high T1rho signal (due to cartilage swelling),
abnormal intrameniscal signal representing meniscal degenera-
tion, and alterations in bone shape or subchondral trabecular
bone40,41. These structural changes may be used in different com-
binations to optimize speciﬁcity or sensitivity for an OA diagnosis,
as has been proposed for MRI ﬁndings42. By ultrasound, additional
pathological anatomic abnormalities, such synovitis and angio-
genesis, can be appreciated in the clinical setting43e45. In some
cases, erosions are also a manifestation of disease, in particular in a
subset of hand OA, which is likely to reﬂect a speciﬁc phenotype46.The prevalence of erosions increases with the sensitivity of imaging
modality; a new MRI-based scoring system has been developed to
better identify and classify features of hand OA47.
Physiologic indicators of joint health and disease
Physiology is the study of the function of body parts and the
body as a whole. Physiology is often complex and involves in-
teractions between multiple organs and tissues. OA can lead to
functional limitation and impairment at the level of the cell, tissue,
organ or person and thereby lead to abnormal functioning at these
levels24,48. Much of OA disease progression is mediated by aberrant
physiological interaction of the components of the musculoskeletal
system, such as aberrant biomechanical forces or a pathologic
response to these forces49. Many interventions, such as exercise
and walking aids, are designed to correct abnormal physiology50.
The physiologic aspect of disease is therefore an integral and
important descriptor of OA. Physiologic measures that might be
used to characterized and grade OA include evaluation of cartilage
degeneration using indentation11,51, dynamic MRI52 including site-
speciﬁc variations in cartilage strain with activity53 constituting a
non-invasive in vivo cartilage “stress test”, and gait biomechanics54.
Traditional OA risk factors, such as strength, joint stability (func-
tional or structural), obesity, and age are all likely to impact joint
physiology but could also impact molecular and anatomic in-
dicators of disease. Moreover, different domains of disease can and
will interact such as malalignment (anatomic indicator) which will
impact gait mechanics joint load and tissue strain (physiologic
indicator).
The illness
Illness refers to the human response to disease, in other words
“what the patient feels when he goes to the doctor”. The latter
description would entail inclusion of patient symptoms, such as
pain aching or stiffness, and disability (a physical or mental
impairment that substantially limits one or more major life activ-
ities of such individual) as deﬁning the illness of OA. There are
multiple potential causes of joint symptoms; symptoms in the
absence of anatomic structural changes of OA cannot currently be
deﬁnitively diagnosed as attributable to an OA disease process55.
Recommendations have already been proposed for making a
diagnosis of concurrent radiographic OA without the need for im-
aging, based on clinical signs (crepitus, restricted movement and
bony enlargement) and symptoms (knee pain, short-lived morning
stiffness and functional limitation)56. Work is in progress to
develop classiﬁcation criteria for early OA (through the OARSI
endorsed International Early Knee OA working group). The valida-
tion of such criteria will be their ability to predict with high like-
lihood, the subsequent development of anatomic OA. In future, the
concurrence of OA-relatedmolecular abnormalities with symptoms
might also allow for a diagnosis of OA despite the absence of
anatomic abnormalities56.
Classically, two types of control groups have been used in OA
studies, those lacking symptoms (illness) or those lacking radio-
graphic OA (anatomic disease). Since disease may not necessarily
coincide with illness, the optimal control group for predicting risk
of early OA will lack illness and disease (at both molecular and
anatomic levels).
Clinical thresholds
To better understand the concepts of disease and illness in OA, it
is instructive to consider the interface of disease and illness for
other organ systems. The thresholds for clinical manifestations of
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women who die suddenly of coronary heart disease have no pre-
vious clinical symptoms of the disease57 (Fig. 4). Other ‘high func-
tioning’ organs, liver and kidney, have 90% excess functional
capacity from birth. For these organ systems, the threshold for
transition from disease to illness is high.
Due to a large “renal reserve”, traditional markers of renal injury
lack the sensitivity and/or speciﬁcity to adequately detect neph-
rotoxicity prior to signiﬁcant loss of renal function58,59. This has, in
part, been responsible for efforts stimulated by the FDA to develop a
kidney damage panel. Such a safety pharmacology panel may be
pertinent to other disease indications60. The function of the kidney
is highly age dependent and GFR declines dramatically with age.
Thus, age alone can account for more than 75% decrease in kidney
function, without any associated illness. This illustrates that the
kidney is an organ with a large overcapacity, and that a large
functional decline is possible before clinical manifestations of
illness may be observed61,62.
The liver is another organ with a large overcapacity. Liver
function can decline as much as 70% before diagnosis and symp-
toms occur such as the presence of full blown cirrhosis (end stage
ﬁbrosis) with portal hypertension63. The liver is the only human
internal organ capable of natural regeneration of lost tissue. In the
absence of an associated illness, as little as 25% of a liver can
regenerate into a whole liver64e67. The liver ﬁbrosis ﬁeld shares
many similar needs with the OA ﬁeld, i.e., a need for anti-ﬁbrotic
treatments and a large medical need for early diagnostics and
prognostics63.
Joints may be more sensitive than internal organs with respect
to threshold for manifestation of illness in the form of clinical
symptoms. In rheumatoid arthritis and OA, clinical manifestations
are incident decades before organ failure e deﬁned as the necessity
for joint replacement. We therefore speculate that the threshold for
clinical manifestations may be 20% loss of joint organ function.
Several studies seem to suggest a low illness threshold related to
the OA disease in some individuals68,69. The association between
illness and radiographic anatomic alteration is very modest e some
patients experience pain very early, and others far later or never.
The presence of multiple joints in the musculoskeletal system
complicates the interaction of disease and illness. Disease and/or
illness may affect “just” one joint or multiple joints simultaneously.
Whereas, a 30% loss of function of the liver or kidney would be
hardly noticeable, a 30% loss of function of even one joint could beFig. 4. Disease vs illness. The tissue functional threshold for establishment of a clinical s
transition from disease to illness for different diseases. The threshold is relatively high in hea
disease to illness (symptoms, disability and joint failure). It is possible that the threshold
“functional reserve”. This contributes to their being silent killer diseases80, in which asymp
outcome for some patients63. AMI ¼ acute myocardial infarction due to coronary heart disdebilitating for an OA patient and have a negative impact on other
joints. Just one abnormal joint can lead to pain while many
abnormal joints can further and alter the pain experience; the
worse the pain the lower the pain threshold70, i.e., illness threshold.
In addition, small losses in cartilage volume are correlated with
pain worsening, suggesting a much lower threshold to illness in
joint disease compared to liver and kidney disease71. Among other
factors, the illness threshold could also be impacted by central
sensitization of pain70 and genetic polymorphisms of pain sensi-
tivity72. The estimate of a 20% threshold is arbitrary. Further
research is needed, including the input of patients, to determine the
exact threshold that deﬁnes the transition to illness in different
individuals and settings.
Draft deﬁnitions of OA
Draft OARSI
“Osteoarthritis is a disorder involving movable joints charac-
terized by cell stress and extracellular matrix degradation initiated
by micro- and macro-injury that activates maladaptive repair re-
sponses including pro-inﬂammatory pathways of innate immunity.
The disease manifests ﬁrst as a molecular derangement (abnormal
joint tissue metabolism) followed by anatomic, and/or physiologic
derangements (characterized by cartilage degradation, bone
remodeling, osteophyte formation, joint inﬂammation and loss of
normal joint function), that can culminate in illness.”
NICE guideline (http://www.nice.org.uk/guidance/index.jsp?
action¼folder&o¼64496)
“Osteoarthritis is characterized pathologically by localized loss
of cartilage, remodeling of adjacent bone and associated inﬂam-
mation. A variety of traumas may trigger the need for a joint to
repair itself. Osteoarthritis includes a slow but efﬁcient repair
process that often compensates for the initial trauma, resulting in a
structurally altered but symptom-free joint. In some people,
because of either overwhelming trauma or compromised repair,
the process cannot compensate, resulting in eventual presentation
with symptomatic osteoarthritis; this might be thought of as ‘joint
failure’. This explains the extreme variability in clinical presenta-
tion and outcome that can be observed between people, and also at
different joints in the same person.”ymptomatic disease differs by organ system. The horizontal dashed lines depict the
rt, liver and kidney disease but anticipated to be relatively low for the transition of joint
will vary according to type of joint disease. Both the kidney and liver have a large
tomatic late stage disease suddenly becomes clinically apparent with a possibly fatal
ease.
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Mathers, and Bruce Pﬂeger (www.who.int/healthinfo/.../bod_
osteoarthritis.pdf)
“Osteoarthritis is a complex disease entity that is difﬁcult to
diagnose and deﬁne. The Subcommittee on Osteoarthritis of the
American College of Rheumatology Diagnostic and Therapeutic
Criteria Committee deﬁned osteoarthritis as “A heterogeneous
group of conditions that lead to joint symptoms and signs which
are associated with defective integrity of articular cartilage, in
addition to related changes in the underlying bone at the joint
margins”73. Clinically, the condition is characterized by joint pain,
tenderness, limitation of movement, crepitus, occasional effusion,
and variable degrees of local inﬂammation.”
Centers for disease control (http://www.cdc.gov/arthritis/basics/
osteoarthritis.htm)
“Osteoarthritis is a disease characterized by degeneration of
cartilage and its underlying bone within a joint as well as bony
overgrowth. The breakdown of these tissues eventually leads to
pain and joint stiffness. The joints most commonly affected are the
knees, hips, and those in the hands and spine. The speciﬁc causes of
osteoarthritis are unknown, but are believed to be a result of both
mechanical and molecular events in the affected joint. Disease
onset is gradual and usually begins after the age of 40.”
Taxonomy of OA e building blocks to phenotypes
In describing and classifying OA, we anticipate that it would be
possible to use a new ‘taxonomy of OA’ (Fig. 2), as building blocks to
systematically describe and classify OA phenotypes or subtypes.We
can gain insights into such a nomenclature by contemplating
clinical descriptions of rheumatoid arthritis and the 2010 classiﬁ-
cation criteria for rheumatoid arthritis of the American College of
Rheumatology (ACR) and EULAR (http://www.rheumatology.org/
practice/clinical/classiﬁcation/ra/ra_2010.asp). As illustrated by
the following example, rheumatoid arthritis is typically described
clinically with a string of qualiﬁers that encompass all three disease
domains (molecular, anatomic and physiologic) and illness: sero-
positive/negative (molecular domain), erosive/non-erosive
(anatomic domain), deforming/non-deforming (anatomic
domain), pattern of joint involvement (anatomic domain), joint
range of motion (physiologic domain), and acute/chronic duration
of symptoms and disability (Illness domain). The ACR/EULAR sys-
tem scores the pattern of joint involvement (anatomic domain),
serology and acute phase reactants (molecular domain), and
duration of symptoms (illness domain). These means of describing
rheumatoid arthritis have served the ﬁeld well. In this regard, we
believe the disease and illness domains, suggested above for OA,
would represent an advance for the OA research ﬁeld.
Needs of the ﬁeld
Risk prediction tools
The FRAX® tool (http://www.shef.ac.uk/FRAX/)74 was developed
under the aegis of the World Health Organization, and designed to
predict the 10-year probabilities of sustaining major osteoporotic
fractures (clinical spine, forearm, hip or shoulder fracture)75. FRAX
is an example of a composite risk score that integrates the risks
associated with clinical risk factors [such as country, age, sex,
weight, height, family history, patient history (e.g., previous frac-
tures)], aswell as bonemineral density (BMD) at the femoral neck75.
The osteoporosis ﬁeld may have been particularly “lucky” as BMD isboth diagnostic of osteoporosis and prognostic for fracture; the OA
ﬁeld has yet to deﬁne such an opportune marker. Although the 10
year risk of fracture can be estimated quite well in the absence of
BMD, BMD data narrow the conﬁdence interval of the estimate.
The FRAX® is highly instructive for possible future advances in
OA. The OA ﬁeld is in need of analogous tools for predicting Risk of
OA Development (ROAD), Risk of OA Progression (ROAP), and
Reliable Early Disease Identiﬁcation (REDI). It will take time to
accumulate good enough predictor data from more than one pop-
ulation to develop these tools. These endeavors are optimally
conducted as an international collaborative project and represent
one of the grand challenges in OA research. We can also anticipate
tools for predicting risk of altered physiology and illness. Pre-
liminary work is ongoing to develop a tool for predicting risk of
radiographic OA development (i.e., anatomic OA based on our
proposed taxonomy)76. To date, models predict 34% of the variance
in radiographic OA incidence (deﬁned as knee Kellgren Lawrence
grade <2 at baseline and grade 2 at follow up of a mean of 4e10
years). The addition of either clinical/questionnaire-based vari-
ables, a genetic risk score or concentration of a biochemical marker,
urinary CTX-II, to age, gender and BMI added little to no predictive
value to the model. However, the addition of symptoms and
baseline radiographic knee OA (Kellgren Lawrence score 1)
improved predictive capabilities of the model. The Kellgren Law-
rence score of 1 was the best predictor of future knee OA and
stronger than age, gender and BMI alone. As aptly stated by Sharma
et al., and in agreement with our taxonomy of OA, incident radio-
graphic OA is likely capturing early progression of disease rather
than disease development. A robust risk predictor of anatomic OA
development will likely require a sensitive and objective molecular
indicator of early disease.
Composite indices of disease and illness
For clinical trials in rheumatoid arthritis, the Disease Activity
Score (DAS) together with ACR20, 50 and 70 response rates are
becoming the gold standard outcomes. At the patient level, the DAS
score is receivingmuch deserved attention for its use in intention to
“treat until remission”, that is until lowering of DAS to below 2.677.
The DAS score is a composite index combining objective (disease)
and subjective (illness) measures including number of tender
joints, number of swollen joints, a serological inﬂammation mea-
sure, such as erythrocyte sedimentation rate (ESR) or C-reactive
protein (CRP) and a general patient health assessment on a visual
analog scale (VAS). The DAS score has been useful for correlating
disease activity with molecular biomarkers in rheumatoid
arthritis78. For OA, it will undoubtedly be useful to develop one or
more composite indices (Fig. 2) combining disease and illness pa-
rameters that could be used for diagnosis, prognosis and moni-
toring of a treatment response.
Knowledge Network of OA
A Knowledge Network of disease would integrate the rapidly
expanding range of information on the causes of OA and allow
OARSI researchers to share and update this information. We hope
that the exercise of posting this draft taxonomy of OA to the web
and engaging the membership in its reﬁnement will be a start to an
expanding range of information on the disease and illness of OA
that can facilitate and invigorate the research enterprise.
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